We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Some Phosphorylated Tau Proteins Indicate Alzheimer’s Disease Prior to Appearance of Cognitive Impairment

By LabMedica International staff writers
Posted on 08 Dec 2020
Print article
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer`s disease (Photo courtesy of Wikimedia Commons)
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer`s disease (Photo courtesy of Wikimedia Commons)
Determination of some specific types of phosphorylated tau proteins enables detection of Alzheimer’s disease before development of cognitive impairment.

The tau proteins are a group of six highly soluble protein isoforms produced by alternative splicing from the MAPT (microtubule-associated protein tau) gene. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). They are less common elsewhere but are also expressed at very low levels in CNS astrocytes and oligodendrocytes. Pathologies and dementias of the nervous system such as Alzheimer's disease (AD) and Parkinson's disease are associated with tau proteins that have morphed into hyperphosphorylated insoluble aggregates called neurofibrillary tangles. Novel immunoassays targeting N‐terminal and mid‐region p‐tau181 and p‐tau217 fragments are available, but head‐to‐head comparison in clinical settings is lacking.

Investigators at the University of Gothenburg (Sweden) and colleagues in Spain, Slovenia, and France measured N‐terminal‐directed p‐tau217 (N‐p‐tau217), N‐terminal‐directed p‐tau181 (N‐p‐tau181), and standard mid‐region p‐tau181 (Mid‐p‐tau181) biomarkers in cerebrospinal fluid (CSF) samples obtained from three cohorts of subjects in order to assess diagnostic performance, concordance, and associations with amyloid beta (Abeta).

Results revealed that about a third of the people evaluated had evidence of Alzheimer’s brain pathology but without any cognitive problems. Nonetheless, the novel p-tau markers correctly identified these emerging abnormalities measured in cerebrospinal fluid and regular blood samples.

Specifically, CSF N‐p‐tau217 and N‐p‐tau181 had better concordance with each other than either had with Mid‐p‐tau181. N‐p‐tau217 and N‐p‐tau181 were significantly increased in early mild cognitive impairment (MCI) without changes in Mid‐p‐tau181 until AD‐dementia. N‐p‐tau217 and N‐p‐tau181 identified Abeta pathophysiology and distinguished MCI‐AD from non‐AD MCI significantly better than Mid‐p‐tau181. P‐tau biomarkers equally differentiated AD from non‐AD dementia.

Senior author Dr. Kaj Blennow, professor of neurochemistry at the University of Gothenburg, said, "A possible way to improve the chances of future therapies is to test them on people in the very early stages of the disease with elusive biological changes but lacking clinical symptoms including memory failings. Candidate drug trials have not been too successful. The practical challenge, however, is that these very tiny initial changes are incredibly difficult to measure reliably. This compromises our chances to identify and recruit preclinical AD patients for clinical trials."

The phosphorylated tau study was published in the November 30, 2020, online edition of the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association.


Related Links:
University of Gothenburg


Print article

Channels

Industry

view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.